volume 32, issue 1, P276-286 2017
DOI: 10.1177/0269216317711826
View full text
|
|
Share

Abstract: Combining opioid analgesia with gabapentinoids did not significantly improve pain relief in patients with tumour-related cancer pain compared with opioid monotherapy. Due to the heterogeneity of patient samples, benefit in patients with definite neuropathic cancer pain cannot be excluded. Clinicians should balance the small likelihood of benefit in patients with tumour-related cancer pain against the increased risk of adverse effects of combination therapy.

Search citation statements

Order By: Relevance

Paper Sections

0
0
0
0
0

Citation Types

0
22
0
2

Publication Types

Select...

Relationship

0
0

Authors

Journals